New 2018 ONclive Peer exchange Panel talking about stage 3 treatments and 2c Trials
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

New 2018 ONclive Peer exchange Panel talking about stage 3 treatments and 2c Trials

› Forums › General Melanoma Community › New 2018 ONclive Peer exchange Panel talking about stage 3 treatments and 2c Trials

  • Post
Viewing 1 reply thread
  • Replies
      • July 28, 2018 at 1:48 pm
      ed williams
      Participant

      For those new to stage 3 melanoma, here is a onclive presentation from 4 years ago to get an idea of how far we have come. Main talk then was about Interferon vs biochemotherapy or new ipi at 10mg/kg trial.https://www.youtube.com/watch?v=jO_iUrOLk5I

      • July 28, 2018 at 4:18 pm
      Bubbles
      Participant

      Thanks for sharing, Edster!  We've come a long way, baby!!!  c

Viewing 1 reply thread
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics